Valuation
- Market cap
- 9,672,000
- Revenue TTM
- $10,330,000
- Net income TTM
- $-129,770,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -1,256.24%
- Debt to equity
- 0.87
Trading
- Volume
- 391,700
- Avg volume
- 597,016
- Day's range
- $0.14 – $0.16
- Shares out
- 67,779,000
- Stochastic %K
- 10%
- Beta
- 1.21
- Analysts
- Hold
- Price target
- $3.50
Company profile
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell t...
Show more
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 857 399 9500
- Website
- https://www.tscan.com
- Address
- 830 Winter Street, Waltham, United States
Latest news
No headlines yet.
Stocktwits
ka1954
Nov 19, 10:34 PM
$TCRX 73m cash and 10m market cap. what the fuck is going on with this stock ? no rebound at all?
0 replies
saladman777
Nov 19, 1:29 PM
$TCRX why isn’t the management doing anything? No news or nothing? On paper, this is hella undervalued but that doesn’t matter if sentiment is trash and management do jack shit. Been waiting to jump into this for sometime but it just keeps finding new lows! What the fuck? Anyone still alive?
1 replies
Double_it_Helix
Nov 15, 10:37 PM
$TCRX All 14 patients tracked in ALLOHA Cohort C showed complete donor chimerism at their last assessment.x
1 replies
pkbull
Nov 13, 2:56 AM
$TCRX this is beyond ridiculous at this point. Most of the small caps are down everyday. Maybe one should only stick up the large caps when it comes to dip buying
0 replies
saladman777
Nov 12, 5:13 PM
$TCRX anyone still here? Is this bottom?
1 replies
d_risk
Nov 12, 12:30 PM
$TCRX TScan Therapeutics, Inc. | 10Q Updated Risk Factors
TScan says it has until Feb. 23, 2027 to regain compliance with Nasdaq’s minimum bid rule. Nasdaq could delist its stock if compliance is not restored.
#RiskFactors #SECFilings
🟢 Added 🟠 Removed
https://d-risk.ai/TCRX?filing=BzGhr9EqgwknqEsKt5Blg
0 replies
StocktwitsEarnings
Nov 12, 12:07 PM
$TCRX Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -
$0.25 up 10.71% YoY
• Reported revenue of
$0.59M down -76.49% YoY
• TScan Therapeutics believes existing cash resources will fund its current operating plan into the fourth quarter of 2027; no revenue, margin, or earnings guidance was provided.
0 replies